AR015940A1 - Derivados de rapamicina que contiene tetrazol con vidas medias acortadas y su uso para la manufactura de un medicamento - Google Patents
Derivados de rapamicina que contiene tetrazol con vidas medias acortadas y su uso para la manufactura de un medicamentoInfo
- Publication number
- AR015940A1 AR015940A1 ARP980104798A ARP980104798A AR015940A1 AR 015940 A1 AR015940 A1 AR 015940A1 AR P980104798 A ARP980104798 A AR P980104798A AR P980104798 A ARP980104798 A AR P980104798A AR 015940 A1 AR015940 A1 AR 015940A1
- Authority
- AR
- Argentina
- Prior art keywords
- manufacture
- tetrazol
- lives
- medicinal product
- derivatives containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Análogo de rapamicina que tiene la formula (I) o una sal o prodroga del mismo farmacéuticamente aceptable que es un agente inmunomodulador y esutil en el tratamiento de restenosis, enfermedades inmunes y autoinmunes, e inhibe cáncer, desarrolofungal , y el rechazo a los tejidos de post-transplante;y su uso para la manufactura de un medicamento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93814497A | 1997-09-26 | 1997-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR015940A1 true AR015940A1 (es) | 2001-05-30 |
Family
ID=25470968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980104798A AR015940A1 (es) | 1997-09-26 | 1998-09-25 | Derivados de rapamicina que contiene tetrazol con vidas medias acortadas y su uso para la manufactura de un medicamento |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1015459B9 (es) |
JP (1) | JP3790424B2 (es) |
KR (3) | KR100833812B1 (es) |
CN (1) | CN1161360C (es) |
AR (1) | AR015940A1 (es) |
AT (1) | ATE297398T1 (es) |
AU (1) | AU745576B2 (es) |
BG (1) | BG64955B1 (es) |
BR (1) | BR9812305A (es) |
CA (1) | CA2303934C (es) |
CO (1) | CO5070656A1 (es) |
CZ (1) | CZ299365B6 (es) |
DE (1) | DE69830502T2 (es) |
DK (1) | DK1015459T3 (es) |
ES (1) | ES2244087T3 (es) |
HK (1) | HK1030771A1 (es) |
HU (1) | HU228368B1 (es) |
IL (2) | IL134607A0 (es) |
NO (1) | NO325813B1 (es) |
NZ (2) | NZ502896A (es) |
PL (1) | PL191212B1 (es) |
PT (1) | PT1015459E (es) |
SI (1) | SI1015459T1 (es) |
SK (1) | SK285408B6 (es) |
TR (1) | TR200000778T2 (es) |
TW (1) | TW557297B (es) |
WO (1) | WO1999015530A1 (es) |
ZA (1) | ZA988750B (es) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6890546B2 (en) * | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
US7399480B2 (en) | 1997-09-26 | 2008-07-15 | Abbott Laboratories | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices |
US7357942B2 (en) * | 1997-09-26 | 2008-04-15 | Abbott Laboratories | Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens |
US7960405B2 (en) | 1998-09-24 | 2011-06-14 | Abbott Laboratories | Compounds and methods for treatment and prevention of diseases |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
ATE347908T1 (de) * | 2002-01-29 | 2007-01-15 | Vlaams Interuniv Inst Biotech | Vorbeugung von gewebeadhäsion |
US20030176455A1 (en) * | 2002-03-13 | 2003-09-18 | Wyeth | Method of inhibiting cell death |
DE60324416D1 (de) | 2002-05-16 | 2008-12-11 | Novartis Ag | Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie |
NZ536558A (en) | 2002-05-27 | 2006-07-28 | Novartis Ag | Bis-aromatic alkanols |
PL375698A1 (en) * | 2002-09-06 | 2005-12-12 | Abbott Laboratories | Medical device having hydration inhibitor |
RU2478378C2 (ru) | 2002-09-24 | 2013-04-10 | Новартис Аг | Органические соединения |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
US7417065B2 (en) | 2003-05-19 | 2008-08-26 | Irm Llc | Immunosuppressant compounds and compositions |
US20110104186A1 (en) | 2004-06-24 | 2011-05-05 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
CN101048152A (zh) | 2004-10-28 | 2007-10-03 | 惠氏公司 | mTOR抑制剂在治疗子宫平滑肌瘤中的应用 |
GB0504544D0 (en) | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
WO2007011708A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
WO2007011707A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
HUE026303T2 (hu) | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával |
ES2611307T3 (es) | 2005-08-30 | 2017-05-08 | University Of Miami | Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25) |
EP1942937A1 (en) | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
US7700614B2 (en) * | 2005-12-14 | 2010-04-20 | Abbott Laboratories | One pot synthesis of tetrazole derivatives of rapamycin |
PL2019657T3 (pl) | 2006-04-26 | 2015-10-30 | Micell Technologies Inc | Powłoki zawierające wiele leków |
BRPI0714945B8 (pt) | 2006-07-25 | 2021-05-25 | Abbott Lab | composições de análogo de rapamicina e processos para preparação de formas cristalinas de análogos de rapamicinas |
US7812032B2 (en) | 2006-07-25 | 2010-10-12 | Abbott Laboratories | Crystalline forms of rapamycin analogs |
US7820812B2 (en) | 2006-07-25 | 2010-10-26 | Abbott Laboratories | Methods of manufacturing crystalline forms of rapamycin analogs |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
CA2679712C (en) | 2007-01-08 | 2016-11-15 | Micell Technologies, Inc. | Stents having biodegradable layers |
TW200901989A (en) | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
WO2009117669A2 (en) | 2008-03-21 | 2009-09-24 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
DK2132228T3 (da) | 2008-04-11 | 2011-10-10 | Emergent Product Dev Seattle | CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf |
CN102083397B (zh) | 2008-04-17 | 2013-12-25 | 米歇尔技术公司 | 具有生物可吸收层的支架 |
EP2303250A1 (en) | 2008-06-20 | 2011-04-06 | Novartis AG | Paediatric compositions for treating1 multiple sclerosis |
US9486431B2 (en) | 2008-07-17 | 2016-11-08 | Micell Technologies, Inc. | Drug delivery medical device |
US20120115840A1 (en) | 2008-12-18 | 2012-05-10 | Lech Ciszewski | Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid |
EP2379499B1 (en) | 2008-12-18 | 2014-04-09 | Novartis AG | Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid |
KR20110112352A (ko) | 2008-12-18 | 2011-10-12 | 노파르티스 아게 | 1-(4-{l-[(e)-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노]-에틸}-2-에틸-벤질)-아제티딘-3-카르복실산의 신규한 다형체 형태 |
US9981072B2 (en) | 2009-04-01 | 2018-05-29 | Micell Technologies, Inc. | Coated stents |
WO2010121187A2 (en) | 2009-04-17 | 2010-10-21 | Micell Techologies, Inc. | Stents having controlled elution |
EP2453834A4 (en) | 2009-07-16 | 2014-04-16 | Micell Technologies Inc | MEDICAL DEVICE DISPENSING MEDICINE |
EP2462165B1 (en) | 2009-08-03 | 2016-05-11 | University of Miami | Method for in vivo expansion of t regulatory cells |
EP2762142A1 (en) | 2009-10-30 | 2014-08-06 | ARIAD Pharmaceuticals, Inc. | Compositions for treating cancer |
EP2531140B1 (en) | 2010-02-02 | 2017-11-01 | Micell Technologies, Inc. | Stent and stent delivery system with improved deliverability |
CA2789622C (en) | 2010-02-11 | 2018-04-03 | Bristol-Myers Squibb Company | Macrocycles as factor xia inhibitors |
US10232092B2 (en) | 2010-04-22 | 2019-03-19 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
EP2563391B1 (en) | 2010-04-27 | 2020-08-26 | Roche Glycart AG | Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor |
CN102234288B (zh) * | 2010-05-06 | 2014-07-02 | 上海医药工业研究院 | 唑他莫司的制备方法 |
CA2805631C (en) | 2010-07-16 | 2018-07-31 | Micell Technologies, Inc. | Drug delivery medical device |
ES2547916T3 (es) | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
SG11201401384UA (en) | 2011-10-14 | 2014-09-26 | Bristol Myers Squibb Co | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
WO2014059214A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
SG11201502605PA (en) | 2012-10-12 | 2015-05-28 | Bristol Myers Squibb Co | Crystalline forms of a factor xia inhibitor |
US9315519B2 (en) | 2012-10-12 | 2016-04-19 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
SG11201404432QA (en) * | 2012-11-30 | 2014-10-30 | Hangzhou Zylox Pharma Co Ltd | Rafamycin analogs and methods for making same |
CA2897826C (en) | 2013-01-09 | 2022-09-27 | Taylor H. Schreiber | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein |
EP2967803B1 (en) | 2013-03-12 | 2023-12-27 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
US9738655B2 (en) | 2013-03-25 | 2017-08-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors |
WO2014186532A1 (en) | 2013-05-15 | 2014-11-20 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
EA201690987A1 (ru) | 2013-11-13 | 2016-10-31 | Новартис Аг | Низкодозовые иммуностимулирующие ингибиторы mtor и их применения |
CA2931684C (en) | 2013-12-19 | 2024-02-20 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
CN103739616B (zh) * | 2013-12-27 | 2015-12-30 | 福建省微生物研究所 | 含噻唑基雷帕霉素类衍生物及其应用 |
US10428331B2 (en) | 2014-01-16 | 2019-10-01 | Musc Foundation For Research Development | Targeted nanocarriers for the administration of immunosuppressive agents |
IL307212A (en) | 2014-01-31 | 2023-11-01 | Bristol Myers Squibb Co | Macrocyclines with P2' heterocyclic groups as factor XIA inhibitors |
NO2760821T3 (es) | 2014-01-31 | 2018-03-10 | ||
EP3811970A1 (en) | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
US10300070B2 (en) | 2014-03-27 | 2019-05-28 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
CA2940671A1 (en) | 2014-04-07 | 2015-10-15 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
WO2015187541A1 (en) | 2014-06-02 | 2015-12-10 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
SG10201913765YA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
DK3183268T3 (da) | 2014-08-19 | 2020-05-11 | Univ Pennsylvania | Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor |
US10081623B2 (en) | 2014-09-04 | 2018-09-25 | Bristol-Myers Squibb Company | Diamide macrocycles that are FXIa inhibitors |
CN114621969A (zh) | 2014-09-17 | 2022-06-14 | 诺华股份有限公司 | 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞 |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
SG11201702895SA (en) | 2014-10-08 | 2017-05-30 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
US10576076B2 (en) | 2015-05-20 | 2020-03-03 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
KR20180080230A (ko) | 2015-11-11 | 2018-07-11 | 노파르티스 아게 | 미오스타틴 길항제의 용도, 이들을 함유하는 조합물 및 그의 용도 |
CN109641947B (zh) | 2016-07-20 | 2023-04-14 | 犹他大学研究基金会 | Cd229 car t细胞及其使用方法 |
US10525083B2 (en) | 2016-10-07 | 2020-01-07 | Novartis Ag | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain |
KR20190089005A (ko) | 2016-11-23 | 2019-07-29 | 노파르티스 아게 | 에베롤리무스, 닥톨리십 또는 둘 다를 사용하여 면역 반응을 증진시키는 방법 |
US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
CA3107349A1 (en) | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
WO2020023418A1 (en) | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
EP3952947A4 (en) | 2019-04-11 | 2024-07-03 | Enclear Therapies Inc | METHODS FOR IMPROVING CEREBRAL SPINAL FLUID AND DEVICES AND SYSTEMS THEREFOR |
EP4240356A1 (en) | 2020-11-03 | 2023-09-13 | RDiscovery, LLC | Therapies for treatment of cancer and phagocytosis-deficiency related diseases |
CA3223081A1 (en) | 2021-07-15 | 2023-01-19 | Samir Mitragotri | Compositions and methods relating to cells with adhered particles |
CN116082362B (zh) * | 2023-01-04 | 2024-05-10 | 山东大学 | 一种可用于合成靶向抗肿瘤药物的氨甲酰美登醇及其合成方法与应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4105761B2 (ja) * | 1993-11-19 | 2008-06-25 | アボット・ラボラトリーズ | ラパミシン(マクロライド)の半合成類似体免疫調節剤 |
CN1235608A (zh) * | 1996-09-09 | 1999-11-17 | 美国家用产品公司 | 烷基化的雷帕霉素衍生物 |
AU4246197A (en) * | 1996-09-09 | 1998-03-26 | American Home Products Corporation | Rapamycin derivatives with unnatural stereochemistries |
-
1998
- 1998-09-08 TW TW087114877A patent/TW557297B/zh not_active IP Right Cessation
- 1998-09-23 ZA ZA988750A patent/ZA988750B/xx unknown
- 1998-09-24 PT PT98949512T patent/PT1015459E/pt unknown
- 1998-09-24 NZ NZ502896A patent/NZ502896A/en not_active IP Right Cessation
- 1998-09-24 CZ CZ20001014A patent/CZ299365B6/cs not_active IP Right Cessation
- 1998-09-24 JP JP2000512835A patent/JP3790424B2/ja not_active Expired - Lifetime
- 1998-09-24 AU AU95819/98A patent/AU745576B2/en not_active Expired
- 1998-09-24 EP EP98949512A patent/EP1015459B9/en not_active Expired - Lifetime
- 1998-09-24 TR TR2000/00778T patent/TR200000778T2/xx unknown
- 1998-09-24 CA CA2303934A patent/CA2303934C/en not_active Expired - Lifetime
- 1998-09-24 DK DK98949512T patent/DK1015459T3/da active
- 1998-09-24 KR KR1020077015322A patent/KR100833812B1/ko not_active IP Right Cessation
- 1998-09-24 CN CNB988094223A patent/CN1161360C/zh not_active Expired - Lifetime
- 1998-09-24 WO PCT/US1998/020111 patent/WO1999015530A1/en not_active Application Discontinuation
- 1998-09-24 NZ NZ514778A patent/NZ514778A/en not_active IP Right Cessation
- 1998-09-24 CO CO98055672A patent/CO5070656A1/es unknown
- 1998-09-24 HU HU0004556A patent/HU228368B1/hu unknown
- 1998-09-24 IL IL13460798A patent/IL134607A0/xx active IP Right Grant
- 1998-09-24 KR KR1020067011149A patent/KR100700319B1/ko not_active IP Right Cessation
- 1998-09-24 AT AT98949512T patent/ATE297398T1/de active
- 1998-09-24 PL PL339455A patent/PL191212B1/pl unknown
- 1998-09-24 SK SK417-2000A patent/SK285408B6/sk not_active IP Right Cessation
- 1998-09-24 DE DE69830502T patent/DE69830502T2/de not_active Expired - Lifetime
- 1998-09-24 ES ES98949512T patent/ES2244087T3/es not_active Expired - Lifetime
- 1998-09-24 SI SI9830781T patent/SI1015459T1/xx unknown
- 1998-09-24 BR BR9812305-0A patent/BR9812305A/pt active Search and Examination
- 1998-09-24 KR KR1020007003197A patent/KR100803639B1/ko not_active IP Right Cessation
- 1998-09-25 AR ARP980104798A patent/AR015940A1/es active IP Right Grant
-
2000
- 2000-02-17 IL IL134607A patent/IL134607A/en not_active IP Right Cessation
- 2000-03-20 NO NO20001438A patent/NO325813B1/no not_active IP Right Cessation
- 2000-04-07 BG BG104316A patent/BG64955B1/bg unknown
-
2001
- 2001-01-05 HK HK01100137A patent/HK1030771A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR015940A1 (es) | Derivados de rapamicina que contiene tetrazol con vidas medias acortadas y su uso para la manufactura de un medicamento | |
CO5011096A1 (es) | Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs | |
AR003938A1 (es) | Compuestos triciclicos de urea utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proteoliticas, composicionfarmaceutica, y el uso de los mismos para la preparacion de medicamentos. | |
AR015900A1 (es) | Una formulacion farmaceutica que comprende voriconazol o un derivado farmaceuticamente aceptable del mismo y un derivado de ciclodextrina. | |
BR0015605A (pt) | Composição e uso | |
DE69713151D1 (de) | Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung | |
CO4290424A1 (es) | Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina | |
ES2175127T3 (es) | Derivados de la quinazolina y su uso. | |
ES2083668T3 (es) | Combinaciones antiviricas que contienen analogos de nucleosidos. | |
AR003427A1 (es) | Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas. | |
AR034343A1 (es) | Combinaciones farmaceuticas | |
ES2062100T3 (es) | Empleo de acetil l-carnitina en el tratamiento terapeutico de cataratas y composiciones farmaceuticas utiles en este tratamiento. | |
BRPI0107493B8 (pt) | substâncias para uso no tratamento de psoríase | |
ES2135342B1 (es) | Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama. | |
AR021086A1 (es) | Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento. | |
DK0479093T3 (da) | Oligosaccharidderivater og deres anvendelse som lægemidler | |
ES2101747T3 (es) | Penciclovir y famciclovir y derivados de guanina relacionados para el tratamiento de infecciones por vih-1. | |
AR035006A1 (es) | Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento. | |
ES2072386T3 (es) | Derivados del penciclovir para el tratamiento de las infecciones de hepatitis-b. | |
FI935066A (fi) | 2-amino-1,2,3,4-tetrahydronaftalenderivat aktivt inverkande pao kardiovaskularsystemet, foerfaranden foer framstaellning av dem och farmaceutiska kompositioner innehaollande dem | |
AR034142A1 (es) | Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion | |
UY26514A1 (es) | " composición para el tratamiento de tejidos danados". | |
ES2191908T3 (es) | 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido. | |
DE59108697D1 (de) | Protein C-haltige pharmazeutische Präparation als Mittel gegen Entzündungen | |
MX9302578A (es) | Agentes antivirales. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |